BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

BioCryst Pharmaceuticals (Nasdaq: BCRX) has granted equity-based compensation to nine newly-hired employees as employment inducements. The compensation package includes:

- Stock options to purchase 36,700 shares at $8.29 per share (equal to closing price on grant date)
- Restricted stock units (RSUs) covering 71,400 shares of common stock

Both options and RSUs were granted on September 2, 2025, and will vest in four equal annual installments. The options have a 10-year term and were granted under BioCryst's Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

News Market Reaction – BCRX

%

1 alert

% News Effect

On the day this news was published, BCRX declined NaN%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted nine newly-hired employees stock options to purchase an aggregate of 36,700 shares, and restricted stock units (RSUs) covering an aggregate of 71,400 shares, of BioCryst common stock. The options and RSUs were granted as of September 2, 2025, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $8.29 per share, which is equal to the closing price of BioCryst common stock on the grant date. The options and RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee’s continued service with the company. Each stock option has a 10-year term. The options and RSUs are subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan and a stock option agreement or restricted stock unit agreement, as applicable, covering the grant.

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO^® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.

BCRXW

Contact:
Investors:
investorrelations@biocryst.com

Media:
media@biocryst.com

FAQ

What equity compensation did BioCryst (BCRX) grant to new employees in September 2025?

BioCryst granted 36,700 stock options at $8.29 per share and 71,400 RSUs to nine newly-hired employees as inducement awards.

What is the vesting schedule for BioCryst's (BCRX) September 2025 inducement grants?

The stock options and RSUs vest in four equal annual installments, beginning on the one-year anniversary of the September 2, 2025 grant date.

What is the exercise price of BioCryst's (BCRX) September 2025 inducement stock options?

The stock options have an exercise price of $8.29 per share, which equals BioCryst's closing stock price on September 2, 2025.

How long is the term for BioCryst's (BCRX) September 2025 inducement stock options?

The stock options have a 10-year term from the grant date of September 2, 2025.